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ABSTRACT
The targeted manipulation of the genetic program of single cells as well as of complete organisms
has strongly enhanced our understanding of cellular and developmental processes and should also
help to increase our knowledge of primary human stem cells, e.g., hematopoietic stem cells (HSCs),
within the next few years. An essential requirement for such genetic approaches is the existence of
a reliable and efficient method to introduce genetic elements into living cells. Retro- and lentiviral
techniques are efficient in transducing primary human HSCs, but remain labor and time consum-
ing and require special safety conditions, which do not exist in many laboratories. In our study, we
have optimized the nucleofection technology, a modified electroporation strategy, to introduce plas-
mid DNA into freshly isolated human HSC-enriched CD34 cells. Using enhanced green fluores-
cent protein (eGFP)-encoding plasmids, we obtained transfection efficiencies of approximately 80%
and a mean survival rate of 50%. Performing functional assays using GFU-GEMM and long-term
culture initiating cells (LTC-IC), we demonstrate that apart from a reduction in the survival rate
the nucleofection method itself does not recognizably change the short- or long-term cell fate of
primitive hematopoietic cells. Therefore, we conclude, the nucleofection method is a reliable and ef-
ficient method to manipulate primitive hematopoietic cells genetically.
INTRODUCTION
FOR MORE THAN 30 YEARS, hematopoietic stem cells(HSCs) have been successfully used in a various num-
ber of clinical applications (1). However, the current un-
derstanding about the molecular and cellular mechanisms
governing the biology of these cells remains limited. In a
variety of different organisms (e.g., Drosophila and
Caenorhabditis elegans) or cellular systems, the under-
standing of different cellular processes was fundamentally
improved by genetic approaches (2). In this regard over- or
ectopic-expression studies, as well as inhibition of expres-
sion by RNA interference, revealed important results, sim-
ilar to naturally occurring mutations. Therefore, an effec-
tive method to manipulate human HSCs or hematopoietic
progenitor cells (HPCs) genetically should help to increase
the current understanding of the basic mechanisms gov-
erning the biology of human HSCs and HPCs. Addition-
ally, an effective transfection method might help to improve
HSC/HPC applications in clinical trials.
In principle, there are different strategies to manipu-
late human HSCs/HPCs genetically, i.e., techniques
based on viral or nonviral gene transfer. Although viral
strategies are highly efficient to transfer genes into pri-
mary cells (up to 90%) (3), they are time consuming and
require special safety precautions to minimize the risk of
1Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Düsseldorf, D-40225 Düsseldorf,
Germany.
2Both authors contributed equally to this work.
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exposure to biohazards (4), most nonviral techniques, e.g.
electroporation, require a prestimulation of the corre-
sponding cells and result in a maximal, regularly non-
permanent transfection efficiency of 30% (5,6).
Recently, a new and highly efficient nonviral method
called nucleofection technology was described. This
modified electroporation strategy, which delivers the
transfected nucleic acids directly into the nuclei of most
cell types investigated so far, permits transient transfec-
tion of primary cells without any prestimulation (7–10).
Indeed, we and others have successfully applied this tech-
nique to transfect freshly isolated human CD34 cells
and have obtained transfection efficiency rates of up to
80% when using green fluorescent protein (GFP)-encod-
ing plasmids (11,12). Because the survival rate of trans-
fected cells dropped significantly with decreasing cell
numbers used in a single nucleofection reaction, we now
have optimized the technology to transfect as little as 2 
105 freshly isolated CD34 cells.
For many experiments, especially those involving im-
mature cell types, it is required that the cell fate of treated
cells is not significantly altered by the transfection
method itself. Therefore, we have also assessed whether
the optimized nucleofection technology has any influence
on the developmental potential of human HSCs/HPCs.
MATERIALS AND METHODS
Cell preparation
Umbilical cord blood (CB) samples were obtained
from donors after informed consent according to the De-
claration of Helsinki. Mononuclear cells were isolated
from individual samples by Ficoll (Biocoll Separating
Solution, Biochrom AG, Berlin Germany) density gradi-
ent centrifugation. Remaining red blood cells were lysed
at 4°C in 0.83% ammonium chloride with 0.1% potas-
sium hydrogen carbonate, followed by a phosphate-
buffered saline (PBS) washing step. CD34 cells were
isolated by magnetic cell separation using the MidiMacs
technique according to the manufacturer’s instructions
(Miltenyi Biotec, Bergisch Gladbach, Germany), yield-
ing CD34 cells of 80.2  8.6 % purity (n  19).
Transfection of CD34 cells
The pEGFP-N1 vector (BD Clontech, Heidelberg, Ger-
many) was amplified in Escherichia coli strain DH12S
(Invitrogen GmbH, Karlsruhe, Germany) and purified us-
ing an Endofree-Plasmid-Maxi-preparation kit (Qia-
gen,Hilden, Germany) according to the manufacturer’s
instructions.
CD34-enriched cells were divided into aliquots of equal
size (2–5  105 cells per aliquot) and were either not trans-
fected, transfected without DNA (mock), or transfected
with 5 g of the vector pEGFP-N1 as described in the text.
By rinsing the transfection cuvettes two times with 1 ml of
I20 [Iscove’s modified Dulbecco’s medium (Invitrogen
GmbH) supplemented with 20% fetal calf serum (FCS;
Biochrom, Berlin, Germany)] transfected cells were trans-
ferred into a 15-ml plastic tube and washed in a total vol-
ume of 10 ml of I20. Pelleted cells were incubated for 15
min in a humidified atmosphere at 37°C and 5% CO2, then
they were resuspended in 1 ml of Myleocult H5100 (Stem
Cell Technologies Inc, Vancouver, Canada) supplemented
with early-acting cytokines (fetal liver tyrosine kinase-3 li-
gand [FLT3L], stem cell factor [SCF], thrombopoietin
[TPO], each at 10 ng/ml final concentration [all PeproTech,
Inc., Rocky Hill, NJ]). Cells were cultured at a density of
1  105 cells/ml, either in the presence or absence of the
general caspase inhibitor Z-VAD-FMK (BD Biosciences,
Heidelberg, Germany) in a humidified atmosphere at 37°C
and 5% CO2.
Flow cytometry and cell sorting
After 2 days, cultivated mock- and GFP-transfected cells,
as well as nontransfected cells, were stained with an anti-
CD34-PeCy5 antibody (clone 581; BD Pharmingen, Hei-
delberg, Germany). CD34 cells of the controls and 
successfully transfected CD34GFP cells were highly pu-
rified using a Coulter EPICS Elite ESP fluorescence cell-
sorting system equipped with the Expo32 software (Beck-
man Coulter, Krefeld, Germany). For functional assays,
defined numbers of appropriate cells were immediately
sorted into corresponding media. Flow cytometric analyses
were performed on a Cytomics FC 500 flowcytometer
equipped with the RXP software (Beckman Coulter).
Functional assays
Primitive hematopoietic progenitors were assessed as
long-term culture initiating cells (LTC-IC) as described be-
fore (13). Briefly, 5,000 cells were sorted into LTBMC
medium consisting of Iscove’s modified Dulbecco medium
(IMDM; Invitrogen GmbH) containing 12.5% horse serum,
12.5% FCS for human myeloid LTC (both Stem Cell Tech-
nologies Inc), 2 mM L-glutamine, 100 U/ml penicillin, and
100 U/ml streptomycin (all Invitrogen GmbH). The cells
were transfered into 96-well tissue culture plates (Costar,
Corning Incorporated, New York) containing irradiated
stroma cells of the murine fetal liver cell line AFT024 (14)
in limiting dilutions (LDA; 22 replicates per concentration:
150, 50, 15, 5 cells/well). Half-medium exchanges were per-
formed once a week. After 5 weeks of culture in a humid-
ified atmosphere at 37°C and 5% CO2, all medium was re-
placed by secondary clonogenic methylcellulose medium
consisting of 1,12% methylcellulose (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) in IMDM (Invitro-
gen GmbH) containing 30% FCS for human myeloid CFC
(Stem Cell Technologies, Inc.), 2 U/ml erythropoietin
(EPO; NeoRecormon; Roche Diagnostics GmbH, Mann-
heim, Germany), and 10% supernatant of the human blad-
der carcinoma cell line 5637 (13,15). Cells were cultured
for another 2 weeks before individual wells were scored for
the presence or absence of secondary colony-forming units
(CFU). Using Poisson statistics and the weighted mean
method, the frequencies of LTC-IC were calculated (15,16).
To perform CFU-GEMM assays, 250 cells were sorted
into MethoCult GF H4434 containing recombinant human
SCF, interleukin-3 (IL-3), granulocyte/macrophage colony-
stimulating factor (GM-CSF), and EPO (Stem Cell Tech-
nologies Inc). The cells were incubated in a humidified
atmosphere at 37°C and 5% CO2. Hematopoietic colonies
were scored after 10–14 days as described before (13,15).
Stromal feeders for LTC-IC assays
The murine fetal liver cell line AFT024 was used as a
stromal feeder layer to support hematopoietic growth in
LTC-IC assays. The cell line was maintained at 33°C in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen
GmbH) containing 20% FCS (Biochrom AG) and 160 M
2-mercaptoethanol (Invitrogen GmbH). The 96-well plates
(Costar, Corning Incorporated) used for the LTC-IC assays
were coated with 0.1% gelatin (Stem Cell Technologies,
Inc.) and seeded with AFT024 cells. Cells were grown to
confluence and irradiated with 2,000ˇrad. One day after ir-
radiation, all medium was replaced by LTBMC medium.
Immunofluorescence and microscopy
Analyses of living cells were performed at 37°C in a
humidified, 5% CO2 atmosphere using a DMIRB inverse
fluorescence microscope (Leica, Bensheim, Germany).
Pictures were taken with an Axiocam digital camera and
processed using Axiovision Software (Carl Zeiss, Goet-
tingen, Germany).
Statistics
Experimental results from different experiments were
reported as mean  standard deviation of the mean (SD).
Significance analyses were performed with the paired
Student’s t-test.
RESULTS
Optimization of the nucleofection technology to
transfect primitive hematopoietic cells
As described recently, we have successfully applied the
nucleofection technology to transfect freshly isolated
CD34 cells with different GFP-encoding plasmids (12).
When following the manufacturer’s instructions (espe-
cially using the nucleofection program U08) and using
more than 5  105 CD34-enriched cells, we obtained sat-
isfying transfection and survival rates. However, when us-
ing less than 5  105 CD34-enriched cells in a single
transfection reaction, the survival rate decreased dramati-
cally, and transfection buffer-derived floe-like structures
arose within the concomitant cell culture. To overcome
these difficulties when transfecting as little as 2  105
CD34-enriched cells, we tested different nucleofection
programs and obtained the best results using the nucleo-
fection program U01. However, even a large proportion of
the transfected cells were still viable at day 1 post trans-
fection (p.t.), most of them died within two days p.t. (data
not shown). In accordance with the original protocol, we
initially cultured transfected CD34 cells in the presence
of the transfection buffer. When the transfection buffer was
removed immediately after the transfection procedure, the
survival rate of cultivated, transfected cells was obviously
increased (data not shown).
Electroporation processes create minipores in cell
membranes that selectively enable the passage of small
ions, resulting in a colloidal osmotic swelling that kills
cells (18,19). Because the postpulse pelleting procedure,
i.e., the immediate precipitation and incubation of pel-
leted, transfected cells for 15 min at 37°C, was reported
to suppress this swelling in human primary hematopoi-
etic stem cells (19,20), we adapted this procedure to our
protocol. Using our improved protocol and 5 g of Endo-
free-preparted plasmid DNA (pEGFP-N1), we now ob-
tain survival rates at day 2 p.t. of 52.9%  18.9% (n 
19) with a mean transfection efficiency of 79.8% 
14.1% (n  19). Upon usage of higher amounts of plas-
mid DNA (10 g), the viability of transfected cells
dropped down (data not shown).
Effects of apoptosis inhibitor Z-VAD-FMK on 
cell survival
Recently, it was shown that the electrotransfection-in-
duced DNA uptake resulted in the induction of large-scale
apoptosis in CD34 cells isolated from peripheral blood,
and that this apoptotic effect was clearly reduced when cas-
pase inhibitors, e.g., Z-VAD-FMK, were added to the post-
pulse culture media (20). To analyze whether inhibition of
caspases also increase the survival rate of nucleofected
CD34 cells, we compared the survival rate of nontrans-
fected, mock-transfected, and GFP-transfected CD34
cells that were cultured in the presence or absence of 
Z-VAD-FMK (20 M or 120 M) for 2 days (n  6). As
depicted in Table 1, we did not find any significant impact
of Z-VAD-FMK on the survival rate of GFP transfected
CD34 cells; a slight increase was observed when added
at a final concentration of 120 M (Table 1).
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Effects of the nucleofection procedure on the cell
growth of CD34 cells
As we have described recently, upon cultivation
CD34 cells increase in size and acquire a dynamic, po-
larized cell morphology, forming a leading edge at the
front and an uropod at the rear pole (12). To analyze
whether the nucleofection procedure has any morpholog-
ical effect on CD34 cells, we compared GFP-transfected,
mock-transfected, and nontransfected cells. We realized
that most cultivated mock- or GFP-transfected CD34
cells acquire a polarized cell shape similar to that of non-
transfected cells (Fig. 1). However, whereas nontrans-
fected CD34 cells reach their final size at culture day 2,
transfected CD34 cells seem to be delayed in their cell
growth. This difference vanishes largely until day 3 post-
transfection (Fig. 2A). It should be mentioned that we ob-
served an additional reduction in cell growth upon treat-
ing transfected cells with Z-VAD-FMK (data not shown).
To analyze whether the transfection procedure has
any obvious influence on the expression of stem cell-
associated surface marker, we compared the content of
CD34 and CD133 expression of nontransfected as well
as of GFP-transfected cells over time. Under the con-
TABLE 1. MEAN SURVIVAL RATE OF CULTURED NONTRANSFECTED AND
TRANSFECTED CELLS 2 DAYS POST TRANSFECTION
Untreated 20 M Z-VAD-FMK 120 M Z-VAD-FMK
Control 84.5%  4.8% 76.3%  12.4% 78.9%  11.0%
p  0.061 p  0.171
Mock 76.7%  10.5% 76.3%  10.7% 76.1%  6.2%
p  0.246 p  0.045
GFP 49.5%  19.0% 52.8%  16.3% 60.4%  7.6%
p  0.130 p  0.044
Content of CD34 cells, 78.8%  11.6%; GFP transfection rate, 85.1%  5.0%; n  6; p Val-
ues are given in relation to corresponding untreated cell fractions.
FIG. 1. Upon cultivation, nontransfected as well as transfected CD34 cells acquire a polarized cell shape. (A) Nontransfected
CD34 cells. (B) Mock-transfected CD34 cells. (C,C) GFP-transfected CD34 cells. All depicted cells were derived from the
same CD34 preparation. Apart from the nucleofection reaction, cells were treated the same. Photos were taken at day 2 post
transfection. GFP-transfected cells are clearly smaller than non- or mock-transfected cells (compare C to A or B, respectively).
Note that most cells, even the GFP-transfected cells, acquired a polarized cell shape.
ditions used, we observed similar dynamics of CD133
and CD34 expression in cultivated nontransfected or
GFP-transfected CD34 cells, respectively (Fig. 2B).
Starting from culture day 3, CD133 and CD34 expres-
sion declines over time leaving approximately 20%
CD133CD34 cells at day 9 p.t. (Fig. 2B). In this con-
text, it is worth mentioning that although the strength
of GFP expression decreases more than 20-fold, ap-
proximately 50% of the cultured offspring of originally
GFP-transfected cells still express GFP after 9 days
(Fig. 2B).
Colony-forming potential of GFP-nucleofected
CD34 cells
To identify potential effects of the nucleofection pro-
cedure on the colony-forming potential of CD34 cells,
we performed CFU-GEMM assays of either transfected
or nontransfected CD34 cells. To allow transfected cells
to recover from the transfection procedure and to express
the trans-gene, they were cultured for 2 days in the 
presence of early-acting cytokines. Then, viable GFP
CD34 cells or CD34 cells of the controls were puri-
fied by cell sorting and transferred in discrete numbers
into the CFU-GEMM assay.
According to our data, GFP transfected CD34 cells
form fewer colonies than non- and mock-transfected con-
trol cells do. However, we did not find any significant
alteration in the ratio of erythroid to myeloid to mixed
colonies in our assays (Table 2). The addition of the cas-
pase inhibitor Z-VAD-FMK to the cultures of the 2-day
lasting recovery phase did not reveal any positive effect
on the frequency of colony formation of transfected or
nontransfected cells (data not shown).
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FIG. 2. Flow cytometric analysis of nontransfected and GFP-transfected cells. (A) Comparison of the size (FSC-height) and gran-
ularity (side scatter) of freshly isolated CD34 (day 0) and GFP-transfected cells (GFP) versus nontransfected cells CD34 cells at
day 2, day 3, or day 9 past transfection. Upon cultivation, cultured cells increase in size and granularity. While cultivated control cells
reach their final size after 2 days, the growth of GFP-transfected cells is delayed approximately 1 day. The “live” gate includes the
living and excludes the dead cells. (B) Expression of CD34 and CD133 in GFP-transfected or nontransfected control cells that were
cultured for 2 or 9 days in the presence of early-acting cytokines. Note that GFP-transfected cells express comparable levels of CD34
and CD133 expression than non-transfected cells. Only cells within the live gate (shown in A) are plotted.
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LTC-IC content of GFP-nucleofected 
CD34 cells
To test if more primitive hematopoietic cells within the
CD34 cell fraction can be transfected without losing
their primitive cell fate, we performed LTC-IC assays of
successfully transfected CD34 cells in comparison to
CD34 cells of the controls. Again, to allow the cells to
recover from the transfection procedure, we cultured
them for 2 days in the presence of early-acting cytokines,
before, either in the presence or in the absence of Z-VAD-
FMK.
According to our results, we detected a slight reduc-
tion in the LTC-IC frequency of transfected versus non-
transfected cells (Table 3). A beneficial effect of the cas-
pase inhibitor was not observed (data not shown).
DISCUSSION
In addition to their clinical relevance, primary human
HSCs provide an attractive and challenging system to
study certain biological processes, e.g., the process reg-
ulating the decision whether a stem cell is maintained as
a stem cell or becomes committed to differentiate. To an-
alyze such processes genetically, it is extremely helpful
to have a reliable and highly efficient method to geneti-
cally manipulate these cells without altering their cell fate
just by the method itself. As we and others have pub-
lished recently, the nucleofection technology is very ef-
ficient method to transfect human HSC-enriched CD34
cells transiently (11,12). Herein we report the optimiza-
tion of the nucleofection protocol to transfect transiently
as little as 2  105 freshly isolated, human HSC-enriched
CD34 cells and the effects of the transfection procedure
on the short-term as well as on the long-term cell fate of
these cells.
Using our optimized conditions and an enhanced (e)
GFP-encoding plasmid, we obtained transfection effi-
ciencies of 80.2%  8.6% (n  19) and survival rates of
52.9%  18.9% at day 2 post transfection. This rate is
higher than that reported of the manufacturers, in which
precultured human CD34 cells were transfected with an
efficiency of 70% and a mean survival rate of less than
40% at day 2 post transfection (11). Optimized classical
electroporation procedures of human CD34 cells result
in transfection efficiencies of around 30% and survival
rates up to 77%, but require a precultivation of trans-
fected cells (5,6), which frequently alters the cell fate of
primitive hematopoietic cells (21,22). In several studies,
freshly isolated CD34 cells were electroporated with
only low transfection efficiencies (6.9% and 12%) (5,23).
Comparable to classical electroporation procedures,
transfection rates obtained with liposome-based tech-
nologies remain far below the efficiency obtained with
the nucleofection technology (24).
Compared to nontransfected control cells (82.3% 
6.0%; n  10), the cell survival rate of mock-transfected
cells is only slightly decreased (74.2%  9.7%; n  10)
whereas many of the GFP-transfected cells die within the
first 48 h post transfection (survival rate, 50.0% 
17.5%; n  10). These results clearly demonstrate that
the lethality observed in our experiments is more related
to the presence of the DNA or to the strong GFP ex-
pression than to the nucleofection procedure itself. In-
TABLE 3. MEAN LTC-IC RATE OF NONTRANSFECTED
AND TRANSFECTED CELLS
LTC-IC in
Survival rate surviving cells
Control 79.7%  7.5%0 5.1%  1.5%
Mock 74.9%  14.3% 4.9%  0.5%
p  0.183 p  0.353
GFP 53.0%  23.8% 3.4%  1.3%
p  0.028 p  0.059
Content of CD34 cells, 79.1%  3.3%; GFP transfection
rate, 66.7%  18.7%, n 4, p Values are given in relation to
corresponding control cell fractions.
TABLE 2. MEAN COLONY FORMATION OF NONTRANSFECTED AND TRANSFECTED CELLS AND RATE OF
WHITE TO RED TO MIXED COLONIES OF COLONIES FORMED
Colonies per 250 Rate of red Rate of white Rate of mixed
Survival rate CD34 cells colonies colonies colonies
Control 82.3%  6.0% 119.6%  64.7% 18.2%  11.3% 62.8%  14.2% 19.0%  11.6%
Mock 74.2%  9.7% 108.6  56.0 15.3%  12.1% 64.0%  16.9% 20.8%  12.8%
p  0.007 p  0.331 p  0.206 p  0.440 p  0.386
GFP 050.5%  17.5% 086.3  76.2 16.0%  10.5% 60.3%  15.8% 23.7%  20.8%
p  0.001 p  0.097 p  0.288 p  0.245 p  0.177
Content of CD34 cells, 78.8%  10.0%; GFP transfection rate, 79.6%  15.6%, n 10, p values are given in relation to
corresponding control cell fractions.
deed the occurrence of DNA-induced cell death in elec-
troporation experiments and the induction of apoptosis
by high levels of GFP expression have been reported be-
fore (19,20,25–27).
Consistent with these observations, we realized a re-
duced colony-forming frequency of isolated GFPCD34
cells in CFU-GEMM and LTC-IC assays compared to that
of isolated CD34 cells of the mock-transfected or non-
transfected controls (Tables 2 and 3). Because the ratio of
erythroid to myeloid to mixed colonies formed by
GFPCD34 cells was largely the same as that of the
CD34 control cells, we assume that the DNA and/or
GFP-induced cell death is rather unspecific than specific
for any of the CD34 cell subtypes. In summary, these
results suggest that DNA transfer into freshly isolated hu-
man CD34 cells by the nucleofection procedure reduces
the overall survival rate but has no major impact on the
cell fate of surviving cells. Therefore, the nucleofection
method is indeed a highly efficient and reliable method
to manipulate primitive hematopoietic cells genetically.
Although we observed that approximately 50% of the
offspring of the initially transfected cells still express low
levels of GFP after 9 days, it was not our aim to analyze
whether these cells were stably transfected or whether
GFP-encoding plasmids remained transiently in those
cells. As mentioned before, culture conditions have a ma-
jor impact on the fate of HSCs and HPCs; under most
stroma-free culture conditions, the majority of primitive
cells become committed within the first few days of cul-
ture (21,22).
Thus, the nucleofection method is a useful technique
to manipulate and dissect the genetic programs that reg-
ulate the maintenance or early commitment of HSCs or
HPCs. As shown here, by performing CFU-GEMM or
LTC-IC assays, it can easily be analyzed whether ex-
pression of certain genes modifies the colony-forming
frequency or the ratio of erythroid to myeloid to mixed
colonies in progenitor assays. As the morphology of cul-
tivated transfected CD34 cells is not recognizably al-
tered in comparison to cultivated control cells, this
method is also very applicable to study the subcellular
distribution of introduced GFP-fusion proteins (12). Ac-
cording to the high transfection efficiency, the method
might also be helpful for in vivo applications of trans-
fected HSCs/HPCs in scientific or clinical approaches.
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